TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10561349
Drug: Dartmouth regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dartmouth regimen (dacarbazine 220 mg/m², cisplatin 25 mg/m² days 1 to 3, carmustine 150 mg/m² day 1 every other cycle, tamoxifen 10 mg orally bid)
Study: 10561349
Drug: Dacarbazine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine 1,000 mg/m²
Study: 8556879
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor treatment (OST)
Study: 8556879
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor treatment (OST) and Chewing exercises
Study: 8369192
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of iohexol (9 mg I/ml)
Study: 8369192
Drug: Viscous preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous preparation of iohexol (9 mg I/ml)
Study: 8369192
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of amidotrizoate (9 mg I/ml)
Study: 8369192
Drug: Aqueous solutions
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solutions of iohexol and amidotrizoate
Study: 11464232
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (oral antioxidant dietary supplement)
Study: 9290026
Drug: (THY 1-)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (THY 1-) fibroblasts non-containing lipids producing insulin-like growth factor 2 (ILGF 2), binding proteins 2 and 4, and epidermal growth factor receptors
Study: 26268636
Drug: Irbesartan 100 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 100 mg/day and amlodipine 5 mg/day (Irb/Am group)
Study: 26268636
Drug: Valsartan 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/day and amlodipine 5 mg/day (Val/Am group)
Study: 25178072
Drug: Fixed irbesartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed irbesartan/amlodipine combination 150/5 mg
Study: 25178072
Drug: Fixed irbesartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed irbesartan/amlodipine combination 150/10 mg
Study: 25178072
Drug: Fixed irbesartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed irbesartan/amlodipine combination 300/5 mg
Study: 25178072
Drug: Fixed irbesartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed irbesartan/amlodipine combination 300/10 mg
Study: 25178072
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with irbesartan/amlodipine combinations
Study: 22412063
Drug: Antiviral hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral hand treatment containing 2% citric acid and 2% malic acid in 62% ethanol (applied every 3 hours while awake)
Study: 22412063
Drug: Antiviral hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral hand treatment
Study: 20696083
Drug: Iota-Carrageenan nasal
Normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iota-Carrageenan nasal spray (0.12%) in saline solution, three times daily for 4 days
Study: 15669890
Drug: Risperidone up
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone up to 6 mg/day
Study: 24746956
Drug: Voucher-based reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher-based reinforcement therapy (VBRT)
Study: 8877926
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg/day for 2 weeks followed by a 13 week drug-free period for a total of 120 weeks
Study: 28629738
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation (hydrocodone/acetaminophen and lorazepam)
Study: 17211861
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (35 mg/m2 on Days 1, 8, and 15 of a 4-week cycle) plus cisplatin (75 mg/m2 on Day 1)
Study: 17211861
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (75 mg/m2 on Day 1) plus cisplatin (75 mg/m2 on Day 1)
Study: 11871190
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) at doses of 100 to 2000 micrograms daily
Study: 11871190
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) at a two-fold increased dose
Study: 7611862
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin‐1 receptor antagonist (100 mg loading dose, followed by continuous infusion of 1.0 mg/kg per hour or 2.0 mg/kg per hour)
Study: 7611862
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin‐1 receptor antagonist (high dose)
Study: 77369
Drug: Routine skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine skin preparation with 70% isopropyl alcohol for 5 seconds
Study: 77369
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin preparation before insulin injection
Study: 31419483
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg plus azithromycin 2 g
Study: 31419483
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg plus azithromycin 2 g
Study: 31402005
Drug: Chlorination at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorination at the point of collection using solid tablet chlorine doser (treatment group)
Study: 28026906
Drug: Successful H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful H. pylori eradication therapy
Study: 23888317
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of encapsulated fish oil (providing 600 mg/day of EPA + DHA) for 9 weeks
Study: 18046534
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin (40 mg/kg)
Study: 18046534
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin (50 mg/kg)
Study: 18046534
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin (60 mg/kg)
Study: 18046534
Drug: Intravenous amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous amikacin (15 mg/kg)
Study: 10936473
Drug: Limb compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limb compression bandage (e.g., Unna's boot) applied weekly
Study: 3903784
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g aluminium hydroxide and 1.6 g magnesium hydroxide per day
Study: 30540640
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion group
Study: 30567725
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 of IV decitabine on days 1 to 10
Study: 30567725
Drug: 1.3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg/m2 of subcutaneous bortezomib on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles
Study: 30567725
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of decitabine and bortezomib
Study: 26857443
Drug: Solubilized vaginal
Normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 10-μg
Study: 26857443
Drug: Solubilized vaginal
Normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 25-μg
Study: 26857443
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablet (Vagifem®) at 10-μg
Study: 26857443
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablet (Vagifem®) at 25-μg
Study: 19238517
Drug: Lamotrigine 325
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 325 mg
Study: 19238517
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid 1,250 mg
Study: 17410456
Drug: Leukocytapheresis (LCAP)
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytapheresis (LCAP) weekly for 5 weeks
Study: 17410456
Drug: Leukocytapheresis (LCAP)
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytapheresis (LCAP) monthly after initial treatment
Study: 17410456
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (Control) after initial remission
Study: 15369805
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (1 microM)
Study: 11600586
Drug: Acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4000 mg/d)
Study: 30395791
Drug: Engaged4Life program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engaged4Life program (technology-assisted self-monitoring of daily activity via pedometers and daily tablet-based surveys; psychoeducation + goal-setting via a 3-hour workshop; peer mentoring via phone 2×/week for 2.5 weeks)
Study: 28978327
Drug: Abiraterone/prednisone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone/prednisone with continuing LHRH therapy
Study: 23209276
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) treatment (160 mg daily) until the day before CABG
Study: 23209276
Drug: No ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ASA treatment (withdrawal 7 days before surgery)
Study: 3328281
Drug: ASA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA treatment
Study: 21515871
Drug: FES with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES with intramuscular (IM) electrodes (FES‐IM)
Study: 9659350
Drug: Inhaled L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled L-arginine 3 g
Study: 9659350
Drug: Inhaled L-alanine
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled L-alanine 3 g
Study: 766555
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg daily for 14 days)
Study: 766555
Drug: Diethylstilboestrol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilboestrol (20 mg daily for 7 days followed by placebo for 7 days)
Study: 766555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 women not receiving any medication)
Study: 24879357
Drug: EPA-DHA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-DHA (400 mg/day)
Study: 24879357
Drug: ALA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (2 g/day)
Study: 21244606
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of tadalafil once daily
Study: 16505089
Drug: Aprotinin (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (30,000 kIU) plus local anaesthetic injection and eccentric exercise
Study: 16505089
Drug: Saline (0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) plus local anaesthetic injections and eccentric exercises
Study: 11328224
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% Vaginal Gel administered once daily in the morning for luteal phase support.
Study: 11328224
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone for luteal phase support.
Study: 16607146
Drug: Successful eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful eradication therapy
Study: 9836101
Drug: Unsuccessful eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unsuccessful eradication therapy
Study: 7926137
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide acetate (GnRH‐a) 7.5 mg with estrogen (0.625 mg/d) and progestin (Medroxyprogesterone acetate 10 mg/d)
Study: 31829833
Drug: Incisional negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative-pressure wound therapy (NPWT)
Study: 31484565
Drug: Low-dose information
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose information program with follow-up email support and resources including an activity tracker (Fitbit) for 3 months and free trial class at the university sports facility
Study: 21081834
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (pravastatin 10 mg/day, fluvastatin 20 mg/day, pitavastatin 1 mg/day, atorvastatin 10 mg/day)
Study: 21081834
Drug: Control (non-statin-treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-statin-treated group with LDL-C < 140 mg/dL)
Study: 11735093
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily) for 8 weeks
Study: 8260300
Drug: Pancuronium (neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (neuromuscular blocker)
Study: 8260300
Drug: Alcuronium (neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium (neuromuscular blocker)
Study: 2888937
Drug: Tranquilizers (diazepam)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranquilizers (diazepam)
Study: 29771080
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid monotherapy
Study: 29771080
Drug: Intratympanic corticosteroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic corticosteroid monotherapy
Study: 29771080
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IT plus systemic corticosteroid)
Study: 29771080
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups combined (systemic, IT, and combination therapy)
Study: 26845463
Drug: 15 patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patients who shifted from heavy smoking to low-moderate levels post treatment
Study: 24465955
Drug: 3 glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 glasses of sparkling white wine (30 g alcohol)
Study: 22183172
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lamivudine (3TC) once daily for 10 days
Study: 22183172
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lamivudine (3TC) once daily for 10 days
Study: 22183172
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Study: 22183172
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Study: 17485597
Drug: Candesartan (Atacand,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (Atacand, Astra Zeneca), 16 mg o.d. for 12 months
Study: 16110036
Drug: Imatinib (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (initial dose)
Study: 7657800
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus fat/heparin
Study: 7657800
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glycerol
Study: 7657800
Drug: Saline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline plus fat/heparin
Study: 7657800
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus fat/heparin (euglycemic)
Study: 7657800
Drug: Insulin (euglycemic)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (euglycemic)
Study: 779562
Drug: DM-prostaglandin E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM-prostaglandin E2 capsule (127 mug)
Study: 779562
Drug: DM-prostaglandin E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM-prostaglandin E2 capsule
Study: 31650500
Drug: Conservative oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative oxygen administration (SpO2 target of 90% with FreeO2 device)
Study: 31650500
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen administration (SpO2 target of ≥ 95% with manual titration)
Study: 31650500
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen administration in retainers
Study: 31650500
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen administration in non-retainers
Study: 30640653
Drug: Single-injection serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection serratus block with L-bupivacaine 0.25% 30mL
Study: 19620065
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus astragalus
Study: 10569127
Drug: Maintenance placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance placebo, nortriptyline, or combination treatment
Study: 10096460
Drug: oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral contraceptives
Study: 29852043
Drug: Trastuzumab for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab for 9 weeks with docetaxel (80 or 100 mg/m2) followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide
Study: 29852043
Drug: Trastuzumab for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab for 1 year with identical chemotherapy
Study: 24768615
Drug: Levodopa (dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (dopaminergic medication)
Study: 22649263
Drug: Polydextrose (PDX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX; 21 g/d)
Study: 20181812
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Vitamin D (1 g elemental Ca as carbonate plus 400 IU vitamin D(3)/d)
Study: 18614429
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg (Test)
Study: 18614429
Drug: Ciproxin 500
Normalized name: Ciproxin 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciproxin 500 mg (Reference)
Study: 11919231
Drug: Early radiotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early radiotherapy with concurrent chemotherapy (arm I)
Study: 11919231
Drug: Late radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late radiotherapy with chemotherapy (arm II)
Study: 10342082
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (1 mg)/ethinyl estradiol (35 micrograms)
Study: 10342082
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (1 mg)/ethinyl estradiol (20 micrograms)
Study: 28448590
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and coenzyme Q10 supplementation (200 μg Se/day as organic selenium yeast tablets and 200 mg/day of coenzyme Q10 capsules)
Study: 19254592
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (OC)
Study: 9215516
Drug: Combined antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antioxidant vitamin capsules providing 400 IU/day vitamin E, 500 mg/day vitamin C, and 6 mg/day beta-carotene
Study: 8267470
Drug: Low-flow bypass
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow bypass (50 mL · kg‐1 · min‐1)
Study: 3302061
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ethionamide, rifampicin, or clofazimine with dapsone)
Study: 3302061
Drug: Dapsone plus
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone plus rifampicin combination